Shares of CorMedix (CRMD) have gained 35.4% over the past four weeks to close the last trading session at 5.28,buttherecouldstillbeasolidupsideleftinthestockifshort−termpricetargetsofWallStreetanalystsareanyindication.Goingbythepricetargets,themeanestimateof13 indicates a potential upside of 146.2%.The mean estimate comprises four short-term price targets with a standard deviation of 4.55.Whilethelowestestimateof9 indicates a 70.5% increase from the current price l ...